| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 23/05/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 30/04/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology Reports First Quarter 2024 Financial Results | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 11/04/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 07/03/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 06/03/2024 | 22:39 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 05/03/2024 | 22:49 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 28/02/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 28/02/2024 | 13:26 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 28/02/2024 | 13:25 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 28/02/2024 | 13:15 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 28/02/2024 | 13:04 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 22/02/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 07/02/2024 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 30/11/2023 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 01/11/2023 | 13:05 | GlobeNewswire Inc. | Nautilus Biotechnology Appoints Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 31/10/2023 | 21:02 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 31/10/2023 | 13:05 | GlobeNewswire Inc. | Nautilus Biotechnology Reports Third Quarter 2023 Financial Results | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 11/10/2023 | 14:05 | GlobeNewswire Inc. | Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 06/09/2023 | 13:30 | GlobeNewswire Inc. | Nautilus Biotechnology to Participate in Upcoming September Investor Conferences | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 04/08/2023 | 14:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Participate in Upcoming August Investor Conferences | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 02/08/2023 | 13:30 | GlobeNewswire Inc. | Nautilus Biotechnology Reports Second Quarter 2023 Financial Results | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 11/07/2023 | 15:23 | GlobeNewswire Inc. | Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 21/06/2023 | 12:03 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 24/05/2023 | 14:05 | GlobeNewswire Inc. | Nautilus Biotechnology to Participate in Upcoming June Investor Conferences | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 02/05/2023 | 12:30 | GlobeNewswire Inc. | Nautilus Biotechnology Reports First Quarter 2023 Financial Results | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 02/05/2023 | 12:01 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 27/04/2023 | 22:09 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 27/04/2023 | 22:08 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 18/04/2023 | 22:05 | GlobeNewswire Inc. | Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023 | NASDAQ:NAUT | Nautilus Biotechnology Inc |
| 23/03/2023 | 13:00 | GlobeNewswire Inc. | Nautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference | NASDAQ:NAUT | Nautilus Biotechnology Inc |